Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPEPPS | P55786 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31509949 | 1.00 | NPEPPS (0.37) | NPEPPSKDM4EHTTFEN1CYP11B1 | |
| SCHEMBL31018954 | 0.84 | AURKA (0.39) | NPEPPSKDM4EHTTFEN1CYP11B1 | |
| SCHEMBL27192163 | 0.84 | AURKA (0.39) | NPEPPSKDM4EHTTFEN1CYP11B1 | |
| SCHEMBL27377609 | 0.83 | PLK4 (0.40) | NPEPPSKDM4EHTTFEN1CYP11B1 | |
| SCHEMBL27377735 | 0.78 | CDK1 (0.40) | NPEPPSKDM4EHTTCYP11B1CYP11B2 | |
| SCHEMBL27377611 | 0.78 | KDM4E (0.42) | NPEPPSKDM4EHTTHSP90AA1GRM4 | |
| SCHEMBL27378023 | 0.77 | PIM1 (0.38) | FEN1CYP11B2HSP90AA1PARP1 | |
| SCHEMBL27378021 | 0.77 | PDE10A (0.38) | NPEPPSKDM4EHTTCYP11B1CYP11B2 | |
| SCHEMBL31509793 | 0.76 | NPEPPS (0.57) | NPEPPSKDM4EHTTFEN1CYP11B1 | |
| SCHEMBL30033042 | 0.74 | KDM4E (0.57) | NPEPPSKDM4EHTTPKMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4565574-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | NPEPPS 168/4885KDM4E 3744/4885HTT 3577/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | NPEPPS 168/4885KDM4E 3744/4885HTT 3577/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | NPEPPS 168/4885KDM4E 3744/4885HTT 3577/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | NPEPPS 168/4885KDM4E 3744/4885HTT 3577/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | NPEPPS 168/4885KDM4E 3744/4885HTT 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.